M
Morten Salomo
Researcher at Copenhagen University Hospital
Publications - 25
Citations - 563
Morten Salomo is an academic researcher from Copenhagen University Hospital. The author has contributed to research in topics: Multiple myeloma & Lenalidomide. The author has an hindex of 10, co-authored 25 publications receiving 417 citations. Previous affiliations of Morten Salomo include Rigshospitalet & University of Copenhagen.
Papers
More filters
Journal ArticleDOI
Oral ixazomib maintenance following autologous stem cell transplantation (TOURMALINE-MM3): a double-blind, randomised, placebo-controlled phase 3 trial
Meletios A. Dimopoulos,Fredrik Schjesvold,Fredrik Schjesvold,Meral Beksac,Roman Hájek,Katja Weisel,Hartmut Goldschmidt,Vladimir Maisnar,Philippe Moreau,Chang-Ki Min,Agnieszka Pluta,Wee Joo Chng,Martin Kaiser,Martin Kaiser,Sonja Zweegman,Maria-Victoria Mateos,Andrew Spencer,Shinsuke Iida,Gareth J. Morgan,Kaveri Suryanarayan,Zhaoyang Teng,Tomas Skacel,Antonio Palumbo,Antonio Palumbo,Antonio Palumbo,Ajeeta B Dash,Neeraj Gupta,Richard Labotka,S. Vincent Rajkumar,Daniel Bar,Alfredo Basso,Dorotea Fantl,Simon He,Neomi Horvath,Cindy Lee,Phillip Rowlings,Kerry Taylor,Tara Cochrane,Fiona Kwok,Sundreswran Ramanathan,Hermine Agis,Niklas Zojer,Alain Kentos,Fritz Offner,Jan Van Droogenbroeck,Ka Lung Wu,Angelo Maiolino,Gracia Martinez,Karla Zanella,Marcelo Capra,Sergio Eduardo Alonso Araujo,Evzen Gregora,Ludek Pour,Vlastimil Scudla,Ivan Spicka,Niels Abildgaard,Niels Holmark Andersen,Bo Amdi Jensen,Carsten Helleberg,Torben Plesner,Morten Salomo,Asta Svirskaite,Richard Delarue,Igor Wolfgang Blau,Aneta Schieferdecker,Veronica Teleanu,Markus Munder,Christoph Röllig,Han-Juergen Salwender,Stephan Fuhrmann,Katja Weisel,Jan Duerig,Matthias Zeis,Stefan Klein,Peter Reimer,Christian Schmidt,Christof Scheid,Karin Mayer,Martin Hoffmann,Markus Sosada,Athanasios Dimopoulos,Sosana Delimpasi,Mary-Christine Kyrtsonis,Achilleas Anagnostopoulos,Zsolt Nagy,Árpád Illés,Miklos Egyed,Zita Borbényi,Gabor Mikala,Najib Dally,Netanel Horowitz,Odit Gutwein,Anatoly Nemets,Iuliana Vaxman,Olga Shvetz,Svetlana Trestman,Rosa Ruchlemer,Arnon Nagler,Tamar Tadmor,Ory Rouvio,Meir Preis,Michele Cavo,Luca De Rosa,Pellegrino Musto,Anna Maria Cafro,Patrizia Tosi,Massimo Offidani,Alessandro Corso,Giuseppe Rossi,Anna Marina Liberati,Alberto Bosi,Kenshi Suzuki,Chiaki Nakaseko,Takayuki Ishikawa,Morio Matsumoto,Hirokazu Nagai,Kazutaka Sunami,Takaaki Chou,Koichi Akashi,Naoki Takezako,Shotaro Hagiwara,Hyeon Seok Eom,Deog-Yeon Jo,Jin Seok Kim,Jae Hoon Lee,Sung-Soo Yoon,Dok Hyun Yoon,Kihyun Kim,Mark-David Levin,Edo Vellenga,Monique C. Minnema,Anders Waage,Einar Haukås,Sebastian Grosicki,Andrzej Pluta,Tadeusz Robak,Herlander Marques,Rui Bergantim,Fernando Campilho,Wee Joo Chng,Yeow Tee Goh,Andrew McDonald,Bernado Rapoport,Miguel Angel Álvarez Rivas,Felipe de Arriba de la Fuente,Yolanda González Montes,Jesus Martin Sanchez,María-Victoria Mateos,Albert Oriol Rocafiguera,Laura Rosiñol,Jesús F. San Miguel,Jaime Pérez de Oteyza,Cristina Encinas,Adrian Alegre-Amor,Ana López-Guía,Per Axelsson,Kristina Carlson,Olga Stromberg,Markus Hansson,Cecile Hveding Blimark,Rouven Mueller,Chih-Cheng Chen,Ta-Chih Liu,Shang-Yi Huang,Po-Nan Wang,Thanyaphong Na Nakorn,Kannadit Prayongratana,Ali Ünal,Hakan Goker,Mehmet Sönmez,Sybiryna Korenkova,Aristeidis Chaidos,Heather Oakervee,Hamdi Sati,Reuben Benjamin,Ashutosh D. Wechalekar,Mamta Garg,Karthik Ramasamy,Gordon Cook,Andrew D Chantry,Matthew W Jenner,Francis K. Buadi,Robert Berryman,Murali Janakiram +183 more
TL;DR: Ixazomib maintenance prolongs PFS and represents an additional option for post-transplant maintenance therapy in patients with newly diagnosed multiple myeloma.
Journal ArticleDOI
Melphalan, prednisone, and lenalidomide versus melphalan, prednisone, and thalidomide in untreated multiple myeloma.
Sonja Zweegman,Bronno van der Holt,Ulf-Henrik Mellqvist,Morten Salomo,Gerard M. J. Bos,Mark-David Levin,Heleen Visser-Wisselaar,Markus Hansson,Annette W. G. van der Velden,Wendy Deenik,Astrid Gruber,Juleon Coenen,Torben Plesner,Saskia K. Klein,Bea Tanis,Damian L. Szatkowski,Rolf Brouwer,Matthijs Westerman,M. (Rineke) B. L. Leys,Harm Sinnige,Einar Haukås,Klaas G. van der Hem,Marc Durian,E. (Vera) J. M. Mattijssen,Niels W.C.J. van de Donk,Marian Stevens-Kroef,Pieter Sonneveld,Anders Waage +27 more
TL;DR: Melphalan, prednisone, and lenalidomide, followed by lenalidmide maintenance therapy, showed promising results without severe neuropathy emerging, and MPR-R has no advantage over MPT-T concerning efficacy.
Journal ArticleDOI
Smoldering multiple myeloma risk factors for progression: a Danish population-based cohort study
Rasmus Sørrig,Tobias Wirenfeldt Klausen,Morten Salomo,Annette Juul Vangsted,Brian Østergaard,Henrik Gregersen,Ulf Christian Frølund,Niels Frost Andersen,Carsten Helleberg,Kristian Thidemann Andersen,Robert Schou Pedersen,Per Trøllund Pedersen,Niels Abildgaard,Peter Gimsing +13 more
TL;DR: It is confirmed that an M‐protein ≥30 g/L and immunoparesis remain important risk factors for progression to MM, and the data do not support recent IMWG proposal of identifying patients with FLC ratio above 100 as having ultra high‐risk of transformation to MM.
Journal ArticleDOI
A Phase I Dose-Escalation Study of Antibody BI-505 in Relapsed/Refractory Multiple Myeloma
Markus Hansson,Peter Gimsing,Ashraf Badros,Titti Martinsson Niskanen,Hareth Nahi,Fritz Offner,Morten Salomo,Elisabeth Sonesson,Morten Mau-Sørensen,Yvonne Stenberg,Annika Sundberg,Ingrid Teige,Jan Van Droogenbroeck,Stina Wichert,Maurizio Zangari,Björn Frendéus,Magnus Korsgren,Martine Poelman,Guido Tricot +18 more
TL;DR: BI-505′s half-life increased with dose while clearance decreased, suggesting target-mediated clearance, and can be safely administered at doses that saturate myeloma cell ICAM-1 receptors in patients.
Journal ArticleDOI
Pomalidomide, bortezomib, and dexamethasone for multiple myeloma previously treated with lenalidomide (OPTIMISMM): outcomes by prior treatment at first relapse.
Meletios A. Dimopoulos,Katja Weisel,Philippe Moreau,Larry D. Anderson,Darrell White,Jesús F. San-Miguel,Pieter Sonneveld,Monika Engelhardt,Matthew Jenner,Alessandro Corso,Jan Dürig,Michel Pavic,Morten Salomo,Eva Casal,Shankar Srinivasan,Xin Yu,Tuong Vi Nguyen,Tsvetan Biyukov,Teresa Peluso,Paul G. Richardson +19 more
TL;DR: The benefit of PVd at first relapse, including immediately after upfront lenalidomide treatment failure and other common first-line treatments, is demonstrated, with similar results regardless of prior bortezomib or SCT.